Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUENCE: Sequential Gilteritinib + Venetoclax + Azacitidine in AML
NCT06696183Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of gilteritinib in acute myeloid leukemia (AML) (4 cohorts), sponsored by Technische Universität Dresden. Primary endpoint: Ratio of dose delivered/dose planned at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06696183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696183.